PMID- 37039724
OWN - NLM
STAT- MEDLINE
DCOM- 20230413
LR  - 20230413
IS  - 1543-0790 (Print)
IS  - 1543-0790 (Linking)
VI  - 21
IP  - 4
DP  - 2023 Apr
TI  - Second-line treatment with CAR T-cell therapy for large B-cell lymphoma.
PG  - 170-178
AB  - The landscape for the treatment of patients with relapsed or refractory (R/R) 
      large B-cell lymphoma (LBCL) has continued to evolve. However, challenges 
      continue to exist, particularly in patients who do not respond to first-line 
      anti-CD20 monoclonal antibody and anthracycline-based therapy or those who 
      experience early relapse. In such patients, the treatment paradigm has changed 
      little in the past 2 decades, with salvage chemotherapy followed by myeloablative 
      chemotherapy and autologous hematopoietic stem cell transplant resulting in 
      historical durable response rates of approximately 40%. Given the success of 
      chimeric antigen receptor (CAR) T-cell therapy in the third- or later-line in the 
      R/R LBCL setting, 3 recent clinical trials (ZUMA-7, BELINDA, and TRANSFORM) have 
      sought to address the clinical need for improved therapies in the high-risk 
      second-line setting for primary R/R disease in the first 12 months. In this 
      review, we analyze these 3 pivotal trials with a focus on clinical trial design, 
      CAR T-cell product attributes, efficacy data, safety data, and patient-reported 
      outcomes when compared with standard of care.
FAU - Lutfi, Forat
AU  - Lutfi F
AD  - Hematologic Malignancies and Cellular Therapeutics, The University of Kansas 
      Medical Center, Kansas City, Kansas.
FAU - Patel, Ameet
AU  - Patel A
AD  - Oncology Hematology Care, Cincinnati, Ohio.
FAU - Mehta, Jasmine
AU  - Mehta J
AD  - Stanford Healthcare, Stanford, California.
FAU - Goyal, Anmol
AU  - Goyal A
AD  - Stanford Healthcare, Stanford, California.
FAU - Dahiya, Saurabh
AU  - Dahiya S
AD  - Blood and Marrow Transplantation and Cellular Therapy, Stanford University, 
      Stanford, California.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Adv Hematol Oncol
JT  - Clinical advances in hematology & oncology : H&O
JID - 101167661
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive/methods
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - *Antineoplastic Agents/therapeutic use
MH  - T-Lymphocytes
MH  - Antibodies, Monoclonal/therapeutic use
EDAT- 2023/04/12 06:00
MHDA- 2023/04/13 06:43
CRDT- 2023/04/11 10:23
PHST- 2023/04/13 06:43 [medline]
PHST- 2023/04/11 10:23 [entrez]
PHST- 2023/04/12 06:00 [pubmed]
PST - ppublish
SO  - Clin Adv Hematol Oncol. 2023 Apr;21(4):170-178.